Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Ibrutinib Imbruvica

Ibrutinib Imbruvica

Approved by the FDA on 29 January 2015, Ibrutinib (Imbruvica®) is used for a lymphoma type called Waldenström macroglobulinemia in affected patients. It also received approval in 2013 for mantle cell lymphoma. It acts on cancer cells at the level of tyrosine kinase receptors. This prevents further cancer cell growth, proliferation and spread to distant tissues.

Its most common side effects are decreased platelets (cells that stop bleeding), diarrhea, anemia, fatigue, pain and swelling.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Ibrutinib Imbruvica

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy